

Shilpa Medicare Limited

Related party transactions

Related parties where control exists and related parties with whom transactions have taken place during period 01st April 2023 to 31st March 2024 are listed below ;
(All amounts are in Indian rupees in Lakhs unless otherwise stated)

List of Related Parties

1. Associates

- a) Maia Pharmaceuticals INC. USA
- b) Reva Pharmachem Pvt Ltd
- c) Auxilla Pharmaceuticals and Research LLP (Investment Entity)

2. Subsidiaries

- a) Zatortia Holdings Ltd. (Wholly- owned Subsidiary)
- b) Shilpa- Therapeutics Pvt. Ltd. (Wholly-owned Subsidiary)
- c) INM Technologies Pvt. Ltd. (Wholly-owned Subsidiary)
- d) INM Nuvent Paint Pvt Limited (Step-down Subsidiary)
- e) Koanna Healthcare Ltd. U.K (Wholly-owned Subsidiary)
- f) Koanna Healthcare GmbH. Austria (Wholly- owned Subsidiary)
- g) Makindus LLC. USA. (Subsidiary)
- h) Shilpa Pharma Inc. (Wholly-owned Subsidiary)
- i) Shilpa Biocare Pvt. Ltd (Formerly known as Shilpa Albumin Pvt. Ltd.) (Wholly-owned Subsidiary)
- j) Shilpa Biologicals Pvt. Ltd. (Wholly-owned Subsidiary)
- k) Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Pvt. Ltd.) (Wholly-owned Subsidiary)
- l) Koanna Healthcare Canada Inc. (Wholly-owned Subsidiary)
- m) INDO BIOTECH SDN. BHD (Wholly-owned Subsidiary)
- n) FTF Pharma Private Limited (Wholly-owned Subsidiary)
- o) Koanna International FZ LLC. UAE (Wholly-owned Subsidiary)
- p) KOANNA HEALTHCARE SPAIN S.L. Spain (Wholly-owned Subsidiary)
- q) Vegil Labs Private Limited (Wholly-owned Subsidiary)
- r) Shilpa Lifesciences Private Limited (Step down Subsidiary of WOS)
- s) Pilnova Pharma INC USA (Wholly-owned Subsidiary)

3. Joint Venture (JV)

- a) Reva Medicare Pvt. Ltd.
- b) Sravathi Advance Process Technologies Pvt. Ltd.
- c) Sravathi AI Technologies Pvt. Ltd. (JV)

4. (i) Key Management Personnel-(KMP)

- a) Vishnukant C. Bhutada - Managing Director
- b) Alpesh Dalal - Chief Financial Officer
- c) Kalakota Sharath Reddy - Whole Time Director
- d) Ritu Tiwari- Company secretary

(ii) Remuneration paid to Directors

- a) Omprakash Inani - Non-executive Chairman
- b) Arvind Vasudev - Independent Director
- c) Hetal Gandhi - Independent Director
- d) Anita Bandyopadhyay- Independent Women Director
- e) Kamal Kishore Sharma - Independent Director
- f) Sirisha Chintapalli -Independent Women Director (retired on 28.09.2022)

5. Relatives

- a) Deepak Kumar Inani
- b) Keshav Bhutada
- c) Madhav Bhutada

- d) Ramakant Inanni
e) Sagar Innani
f) Ravi Innani
g) Triveni Inani

6. Enterprises having common Directors/ Board of Trustees

- a) Shilpa Foundation
b) Mohini Infra (P) Ltd

Sl. No.	Name of the related party	Relationship	Description of transaction	01st April 2023 to 31st March 2024	Balance as at 31st March 2024 (Payable) / Receivable	01st April 2023 to 31st Dec 2023	Balance as at 31st Dec 2023 (Payable) / Receivable	01 st April 2022 to 31 st Mar 2023	Balance as at 31st Mar 2023 (Payable) / Receivable
				Transaction		Transaction		Transaction	
A	Remuneration paid to Key Management Personnel								
i)	Vishnukant.C. Bhutada	Managing Director	Salary and perquisites/Managerial commission*	350.00	(14.48)	262.50	(14.48)	555.80	(202.44)
ii)	Kalakota Sharath Reddy	Whole Time Director	Salary and perquisites	162.62	(7.71)	121.96	(7.70)	158.65	(5.80)
iii)	Alpesh Dalal	Chief Financial Officer	Salary and perquisites	124.67	(5.57)	102.52	(5.57)	119.16	(3.02)
iv)	Ritu Tiwari	Company Secretary	Salary and perquisites	45.10	(2.39)	36.45	(2.39)	45.00	(2.71)
B	Remuneration paid to other Directors								
i)	Omprakash Inani	Chairman & Non-executive Chairman	Sitting Fees	3.50	-	2.50	-	2.00	
ii)	Sirisha Chintapalli	Independent Woman Director	Sitting Fees			-	-	1.50	
iii)	Arvind Vasudev	Independent Director	Sitting Fees	-	-	-	-	0.50	
iv)	Anita Bandyopadhyay	Independent Director	Sitting Fees	-	-				
v)	Hetal Madhukant Gandhi	Independent Director	Sitting Fees	-	-	-	-	0.50	
vi)	Kamal Kishore Sharma	Independent Director	Sitting Fees	-	-				
vii)	Arvind Vasudev	Independent Director	Remuneration	30.00	(6.75)	22.50	(6.75)	29.50	(6.75)
viii)	Hetal Madhukant Gandhi	Independent Director	Remuneration	40.00	(9.00)	30.00	(9.00)	39.50	(9.00)
ix)	Anita Bandyopadhyay	Independent Director	Remuneration	18.00	(4.05)	13.50	(4.05)	11.50	(4.05)
x)	Kamal Kishore Sharma	Independent Director	Remuneration	30.00	(6.75)	22.50	(6.75)	22.50	(6.75)
C	Relative								
i)	Deepak Kumar Inani	Relative to Director	Salary and perquisites	86.82	(4.60)	66.30	(4.60)	80.36	(3.92)
ii)	Keshav Bhutada	Relative to Managing Director	Salary			-	-	24.76	(0.64)
iii)	Madhav Bhutada	Relative to Managing Director	Salary			-	-	24.76	(0.64)
iv)	Ramakant Innani	Finance Manager	Salary and perquisites	91.47	(4.89)	69.33	(4.89)	84.03	(4.09)
v)	Ravi Kumar Innani	General Manager	Salary and perquisites	62.86	(3.08)	47.58	(3.07)	57.66	(1.90)
vi)	Sagar Innani	Relative to Managing Director	Salary and perquisites	12.40	(0.82)	9.12	(0.81)	10.80	(0.30)
vii)	Keshav Bhutada	Relative to Managing Director	Rent			-	-	1.20	-
viii)	Madhav Bhutada	Relative to Managing Director	Rent			-	-	1.20	-
ix)	Triveni Inani	Relative to Director	Rent			-	-	0.85	-
D	Others								

Sl. No.	Name of the related party	Relationship	Description of transaction	01st April 2023 to 31st March 2024	Balance as at 31st March 2024 (Payable) / Receivable	01st April 2023 to 31st Dec 2023	Balance as at 31st Dec 2023 (Payable) / Receivable	01 st April 2022 to 31 st Mar 2023	Balance as at 31st Mar 2023 (Payable) / Receivable
				Transaction		Transaction		Transaction	
i)	Koanna Healthcare GmbH, Austria	Wholly owned Subsidiary	Sales of Goods or Service			-	-	91.08	-
			Interest Income (Loan)	318.98		240.35	-	308.04	-
			Purchases of Goods or Service			-	-	-	-
			Expenses incurred on behalf of the related party			-	-	-	-
			Loan given during the year			-	-	-	-
			Loan repaid during the year			-	-	248.32	-
			Loan given during the year	66.88		66.88	-	-	-
			Loan Receivable		4,514.93	-	4,604.37	-	4,417.19
			Trade Receivable		30.34	-	31.13	-	411.91
			Trade Payable			-	-	-	90.18
			Interest accrued but not received (Loan)		320.76	-	240.35	-	308.04
			Investment in equity Shares		77.63	-	77.63	-	77.63
			Sales Return	390.21		390.21	-	-	-
ii)	Koanna Healthcare Ltd, United Kingdom	Wholly owned Subsidiary	Interest Income (Loan)	77.73		59.27	-	58.07	-
			Trade Receivable			-	-	-	-
			Loan given during the year	51.86		51.86	-	107.14	-
			Loan repaid during the year	26.91		26.91	-	-	-
			Loan Receivable		907.35	-	914.34	-	852.40
			Interest accrued but not received (Loan)		79.45	-	59.27	-	58.07
			Investment in equity Shares		0.10	-	0.10	-	0.10
iii)	Shilpa Therapeutics Pvt. Ltd.	Wholly owned Subsidiary	Purchases of Goods or Service	25.25		6.23	-	115.21	-
			Sales of Goods or Service	4.08		2.94	-	10.89	-
			Interest Income (Loan)	545.43		396.70	-	415.76	-
			Dividend Income (Preference shares)	3.20		2.40	-	3.20	-
			Corporate Guarantees to Banks **			-	-	-	3,000.00
			Trade Receivable		-	-	0.39	-	-
			Loan given during the year	1,925.76		1,896.76	-	1,135.00	-
			Loan repaid during the year			-	-	-	-
			Loan Receivable		7,965.06	-	7,936.06	-	6,039.30
			Trade Payable		(0.58)	-	-	-	(107.51)
			Advance against purchase			-	-	-	-
			Interest accrued but not received (Loan)Net of TDS		490.89	-	396.70	-	374.19
			Dividend accrued but not received (Pref Share)		32.01	-	26.41	-	28.81
			Income on Corp Gauarantee	12.10		12.10	-	15.59	-
			Investment in equity Shares		1,112.46	-	1,112.46	-	1,112.46
			Investment in Preference equity Shares		40.00	-	40.00	-	40.00
iv)	Zatortia Holdings Limited	Wholly owned Subsidiary	Loan Receivable	-	-	-	-	-	-
			Investment written off			-	-	58.53	1.34
			Investment in Equity Shares	-	-	-	-	-	-
			Advances			-	-	-	4.53
v)	INM Technologies Pvt. Ltd.	Wholly owned Subsidiary	Purchases of Goods or Service			-	-	-	-

Sl. No.	Name of the related party	Relationship	Description of transaction	01st April 2023 to 31st March 2024	Balance as at 31st March 2024 (Payable) / Receivable	01st April 2023 to 31st Dec 2023	Balance as at 31st Dec 2023 (Payable) / Receivable	01 st April 2022 to 31 st Mar 2023	Balance as at 31st Mar 2023 (Payable) / Receivable
				Transaction		Transaction		Transaction	
vi)	Reva Medicare Pvt. Ltd.	Joint Venture	Purchases of Capital goods			-	-	27.87	-
			Interest Paid (Loan)	67.62		50.51	-	66.77	-
			Dividend Income (Preference shares)	260.30		196.12	-	260.30	-
			Advance against purchase			-	-	-	-
			Loan received	84.00		-	-	-	-
			Loan Payable		(974.33)	-	(895.33)	-	(890.33)
			Interest accrued but not paid (Loan)		(60.86)	-	(9.59)	-	(60.10)
			Dividend accrued but not received (Preference shares)		1,965.32	-	1,508.90	-	1,705.02
			Investment in Equity Shares	-	113.25	-	113.25	-	113.25
			Investment in Pref Shares	-	4,246.77	-	4,246.77	-	4,246.77
vii)	Maia Pharmaceuticals INC. USA	Associates	Commission charges	77.40		68.07	-	93.16	-
			Sales of Goods or Service	4.20		3.15	-	4.20	-
			Trade Payable		(8.25)	-	(112.62)	-	(120.27)
			Commission Accrued but not paid		(70.27)	-	(82.03)	-	(36.32)
			Trade Receivable		0.41	-	1.24	-	-
			Investment in equity shares		0.50	-	0.50	-	0.50
								-	-
			Investment in equity shares		795.69	-	795.69	-	795.69
			Trade receivable		201.16	-	201.16	-	201.16
								-	-
viii)	Shilpa Pharma INC. USA	Wholly-owned Subsidiary						-	-
			Interest Income (Loan)	199.23		143.53	-	124.44	-
			Commission	83.23		83.25	-	-	-
			Interest accrued but not received (Loan)		201.20	-	143.53	-	124.44
			Commission Accrued but not paid			-	-	-	-
			Loan Given during the year	593.40		510.33	-	442.75	-
			Loan repaid during the year			-	-	-	-
			Loan Receivable		2,430.35	-	2,339.73	-	1,808.77
			Investment in equity shares		0.07	-	0.07	-	0.07
								-	-
ix)	Sravathi Advance Process Technologies Pvt. Ltd.	Joint Venture	Purchases of Goods or Service			-	-	-	-
			Trade Payable			-	-	-	-
			Investment in equity shares	-	3,995.58	-	3,995.58	-	6.50
			Investment in Pref Shares	257.50	-	257.50	-	889.00	3,732.50
								-	-
								-	-
								-	-
								-	-
								-	-
								-	-
x)	Shilpa Biocare Pvt. Ltd (Erstwhile Shilpa Albumin Pvt. Ltd.)	Wholly-owned Subsidiary						-	-
			Sales of Goods or Service			-	-	20.94	-
			Sales of Capital Goods	64.00		13.28	-	-	-
			Purchase of Capital Goods	182.76		182.76	-	-	-
			Purchase of goods						
			Interest Income (Loan)	1,439.21		1,054.09	-	931.85	-
			Expenses incurred on behalf of the related party			-	-	-	-
			Loan given during the year	4,281.00		3,631.66	-	10,967.46	-
			Loan repaid during the year	135.00		-	-	-	-
			Loan Receivable		21,467.29	-	20,114.29	-	16,482.62

Sl. No.	Name of the related party	Relationship	Description of transaction	01st April 2023 to 31st March 2024	Balance as at 31st March 2024 (Payable) / Receivable	01st April 2023 to 31st Dec 2023	Balance as at 31st Dec 2023 (Payable) / Receivable	01 st April 2022 to 31 st Mar 2023	Balance as at 31st Mar 2023 (Payable) / Receivable
				Transaction		Transaction		Transaction	
xi)	Shilpa Biologicals Pvt. Ltd.	Wholly-owned Subsidiary	Interest accrued but not received (Loan)Net of TDS		1,295.29	-	1,054.09	-	838.66
			Trade Receivable		47.42	-	14.81	-	3.26
			Corp Guarantee to Banks ****		15,000.00	-	15,000.00	-	15,000.00
			Corporate Guarantee Income	14.26		10.34	-	3.77	-
			Investment in equity shares(financial gaurantee)	52.44	2,052.44	32.42	2,077.88	45.46	2,045.46
			Trade Payable	-	-		-	-	-
								-	-
			Expenses incurred on behalf of the related party			-	-	-	-
			Sales of Goods or Service	31.40		21.52	-	17.57	-
			Sales of Capital Goods	1.52		1.52	-	-	-
			Sales other consumables	8.66					
			Purchases of Goods or Service	12.47		12.47	-	-	-
			Purchases of Capital goods	83.28		78.08	-	36.95	-
			Expenses incurred on behalf of the related party			-	-	-	-
			Expenses incurred by related party on behalf of Shilpa			-	-	-	-
			Interest Income (Loan)	4,017.50		2,990.19	-	3,225.28	-
			Trade Receivable		19.55	-	0.58	-	-
			Trade Payable			-	-	-	-
			Loan given during the year	5,996.00		7,993.75	-	8,428.04	-
			Loan repaid during the year	150.00	-	-	-	-	-
xii)	Shilpa Foundation	Trust in which key management are the board of trustees or Director are Trustee	Loan Receivable		55,396.34	-	54,641.34	-	46,647.59
			Interest accrued but not received (Loan) Net of TDS		3,615.75	-	2,990.19	-	2,902.75
xiii)	Mohini Infra (P) Ltd	Company in which key management are the board of trustees or Director	Income on Corp Gaurantee/Written back	96.45		88.24	-	85.35	-
			Corporate Guarantees to Banks/NCD ***	10,000.00	10,000.00	10,000.00	10,000.00	-	25,000.00
xiv)	FTF PHARMA PVT LTD	Wholly-owned Subsidiary	Investment in equity shares		3,360.93	-	3,360.93	-	3,360.93
			Corporate Social Responsibility Expenses	241.71		-	-	397.54	-
			Godown Rent	-	-	-	-	1.95	-
			Trade Payable	-	-	-	-	-	-
								-	-
			Sales of Goods or Service	31.66		30.52	-	3.86	-
			Sales of capital Goods	544.17		74.41	-	-	-
			Sale of Consumables	3.32		-	-	-	-
			Purchases of Goods or Service	142.55		48.97	-	335.41	-

Sl. No.	Name of the related party	Relationship	Description of transaction	01st April 2023 to 31st March 2024	Balance as at 31st March 2024 (Payable) / Receivable	01st April 2023 to 31st Dec 2023	Balance as at 31st Dec 2023 (Payable) / Receivable	01 st April 2022 to 31 st Mar 2023	Balance as at 31st Mar 2023 (Payable) / Receivable
				Transaction		Transaction		Transaction	
xv)	Koanna Healthcare Canada INC	Wholly-owned Subsidiary	Expenses incurred on behalf of the related party			-	-	-	-
			Advance to Vendor			-	-	-	-
			Trade Receivable		606.09	-	103.86	-	-
			Advance paid against PO			-	-	-	227.57
			Corporate Guarantees to Banks ****		-	-	-	-	1,204.50
			Investment in Equity shares		6,577.97	-	6,577.97	-	6,577.97
			Investment in Pref shares		390.00	-	390.00	-	390.00
			Dividend on Pref Shares	20.93		15.70	-	-	-
			Dividend accrued but not received (Preference shares)		20.93	-	15.70	-	-
			Trade Payable		(1.17)	-	(7.15)	-	-
xvi)	Auxilla Pharmaceuticals and Research LLP	Investment Entity	Interest Income (Loan)	86.73		63.64	-	61.86	-
			Loan given during the year	184.04		137.89	-	228.86	-
			Loan repaid during the year			-	-	91.07	-
			Loan Receivable		1,170.86	-	1,146.41	-	972.09
			Interest accrued but not received (Loan)		87.15	-	63.64	-	61.86
			Investment in equity shares		0.06	-	0.06	-	0.06
								-	-
			Sales of Goods or Service			-	-	-	-
			Purchases of Goods or Service			-	-	78.36	-
			Trade Receivable			-	-	-	-
xvii)	Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Pvt. Ltd.)	Wholly owned Subsidiary	Trade Payable			-	-	-	-
			Sales of Goods and services	1,207.65		902.10	-	903.56	-

Sl. No.	Name of the related party	Relationship	Description of transaction	01st April 2023 to 31st March 2024	Balance as at 31st March 2024 (Payable) / Receivable	01st April 2023 to 31st Dec 2023	Balance as at 31st Dec 2023 (Payable) / Receivable	01 st April 2022 to 31 st Mar 2023	Balance as at 31st Mar 2023 (Payable) / Receivable
				Transaction		Transaction		Transaction	
			Wind Energy Sales	228.29		199.80		285.76	
			Sale of Capital Goods	204.97		202.21	-	-	-
			Purchase of goods	8,146.55		5,747.18	-	4,129.45	-
			Interest paid	9.24		-	-	32.60	-
			Interest Income (Loan)	25.67		25.67	-	-	-
			Interest accrued but not received (Loan)		-	-	25.67	-	-
			Trade Payable		(3,438.24)	-	(2,618.18)	-	(574.67)
			Loan given during the year	1,080.00	-	-	-	892.22	-
			Loan repaid during the year	1,080.00	-	-	-	951.50	-
			Loan Receivable		-	-	-	-	-
			Trade Receivable		43.38		121.75	-	583.45
			Slump Sales Consideration			-	-	47,228.00	-
			Slump Sales Consideration Receivable			-	-	-	31,601.08
			Investment in Equity shares		1,000.00	-	1,000.00	-	1,000.00
			Loan Received	4,075.00		-	-	-	-
			Loan Repaid	2,675.00		-	-	-	-
			Loan Payable		(1,376.89)	-	-	-	-
			Interest due but not paid (Loan)		(8.32)	-	-	-	-
			Corporate Guarantees to NCD	35,000.00	35,000.00	35,000.00	35,000.00	-	-
			Corporate Guarantee Income	50.00		30.69	-	-	-
xviii)	INDO BIOTECH SDN. BHD	Wholly owned Subsidiary						-	-
			Interest Income (Loan)	85.32		64.69	-	81.81	-
			Interest accrued but not received (Loan)		231.80	-	194.02	-	81.81
			Loan Receivable		942.13	-	939.22	-	929.05
xix)	Koanna International FZ LLC. UAE	Wholly owned Subsidiary	Investment in equity shares		4.42	-	4.42	-	4.42
								-	-
			Interest Income (Loan)	53.44		38.99	-	39.17	-
			Interest accrued but not received (Loan)		93.68	-	-	-	39.17
			Loan given during the year	37.17		16.40	-	238.21	-
			Loan repaid during the year			-	-	-	-
			Loan Receivable		608.63	-	585.97	-	563.19
			Investment in Equity shares		1.98	-	1.98	-	1.98
xx)	Koanaa Healthcare Spain, S.L. Spain	Wholly owned Subsidiary						-	-
			Sales of Goods and services	292.98		292.98	-	-	-
			Interest Income (Loan)	60.46		44.63	-	38.15	-
			Interest accrued but not received (Loan)		60.80	-	44.63	-	38.15
			Purchase of Goods /Service	96.06		96.06	-	-	-
			Purchase of Capital Goods	21.25					
			Loan given during the year	125.57		125.57	-	234.60	-
			Loan repaid during the year			-	-	-	-
			Loan Receivable		870.60	-	887.85	-	739.26
			Investment in Equity shares		6.24	-	6.24	-	6.24
			Corp Gaurantee		141.04	-	141.04	-	143.37
			Trade receivable		75.78	-	77.28	-	-
			Trade Payable		(115.98)	-	(96.61)	-	-
								-	-
xxi)	Vegil Labs Private Limited	Wholly owned Subsidiary	Interest Income (Loan)	22.22		22.16	-	10.18	-
			Expenses incurred on behalf of the related party			-	-	-	-

Sl. No.	Name of the related party	Relationship	Description of transaction	01st April 2023 to 31st March 2024	Balance as at 31st March 2024 (Payable) / Receivable	01st April 2023 to 31st Dec 2023	Balance as at 31st Dec 2023 (Payable) / Receivable	01 st April 2022 to 31 st Mar 2023	Balance as at 31st Mar 2023 (Payable) / Receivable
				Transaction		Transaction		Transaction	
xxii)	Shilpa Lifesciences Private Limited	Step down Subsidiary	Interest accrued but not received (Loan)		-	-	22.16	-	9.16
			Trade receivable			-	-	-	-
			Loan given during the year	150.00		159.16	-	280.25	-
			Loan repaid during the year	439.41		300.00	-	-	-
			Loan Receivable		-	-	139.41	-	280.25
			Investment in Equity shares		951.00	-	951.00	-	951.00
			Advance receivable			-	-	-	-
			Loan Received	650.59	-		-	-	-
			Loan Payable		(650.59)				
			Interest Paid	7.80					
			Interest accrued but not paid (Loan)		(7.02)				
			Interest Income (Loan)	20.35		15.26	-	22.00	-
			Expenses incurred on behalf of the related party			-	-	-	-
			Other Receivable			-	-	-	-
xxiii)	Makindus LLC USA	Wholly owned Subsidiary	Interest accrued but not received (Loan)		18.32	-	15.26	-	16.97
			Loan given during the year	19.47		19.47	-	7.83	-
			Loan repaid during the year	2.50		-	-	-	-
			Loan Receivable		270.05	-	272.55	-	253.08
			Investment in Equity shares		454.20	-	454.20	-	454.20
xiv)	Pilnova Pharma INC USA	Wholly owned Subsidiary	Investment in Equity shares	0.08	0.08	0.08	0.08	-	-
			Loans Given during the year	291.81		83.12	-	-	-
			Loan receivable		291.81	-	83.12	-	-
			Interest received	3.46		0.23	-	-	-
			Interest accrued but not received		3.50	-	0.23	-	-
xxv)	Reva Pharmachem Pvt Ltd	Wholly owned Subsidiary	Investment in Equity shares					-	-
			Written off	-	-	-	-	10.00	-

a) The above disclosures include related parties as per Ind AS 24 on "Related Party Disclosures" and Companies Act, 2013.

b) As the provisions for gratuity are obtained on an actuarial basis for the Company as a whole amounts pertaining to the Key Management Personnel are not specifically identified and hence not included in the

** the outstanding liabilities against corporate guarantee given to Non-convertible Debenture holders on behalf of Shilpa Pharma Lifesciences Ltd. is for the financial period ended 31.03.2024 is Rs.35000.00 (As on 31.03.2023 Rs. 0.00)

*** the outstanding liabilities against corporate guarantee given to Non-convertible Debenture holders on behalf of Shilpa Biologicals Pvt. Ltd. is for the financial period ended 31.03.2024 is Rs. 10000.00(As on 31.03.2023 Rs.0.00)

**** the outstanding liabilities against corporate guarantee given to banks on behalf of FTF Pharma Pvt. Ltd. is for the financial period ended 31.03.2024 is Rs. 0.00(As on 31.03.2023 Rs.228.80)

***** the outstanding liabilities against corporate guarantee given to banks on behalf of Shilpa Biocare Pvt Ltd. is for the financial period ended 31.03.2024 is Rs.11015.99 (As on 31.03.2023 Rs. 6429)

c) The Copmany Reva Pharmachem P Ltd has applied for strike off on 26.03.2024